Investors deposited $819 million into health care and biotech funds this week — the largest weekly infusion of money into the sector since last July, according to a new report.
The timing of the big biotech inflow is also significant, coming in the same week that President Trump rolled out a series of proposals to lower prescription drug prices. Despite some sharp rhetoric, the snap judgment from Wall Street was that Trump’s plan would have limited impact on biotech and pharmaceuticals companies.
About the Author Reprints
